Vaxart (NASDAQ:VXRT) Stock Passes Below Two Hundred Day Moving Average - Should You Sell?

Vaxart, Inc. (NASDAQ:VXRT - Get Free Report) shares passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.61 and traded as low as $0.43. Vaxart shares last traded at $0.43, with a volume of 2,267,700 shares traded.

Wall Street Analyst Weigh In

Separately, B. Riley lowered their target price on shares of Vaxart from $2.50 to $2.00 and set a "buy" rating for the company in a research note on Thursday, March 27th.

Vaxart Price Performance

The company has a market capitalization of $102.63 million, a P/E ratio of -1.10 and a beta of 1.57. The company has a fifty day moving average price of $0.43 and a 200 day moving average price of $0.60.

Vaxart (NASDAQ:VXRT - Get Free Report) last posted its earnings results on Thursday, March 20th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.10) by $0.05. The company had revenue of $15.19 million for the quarter, compared to analysts' expectations of $15.68 million. Vaxart had a negative return on equity of 110.46% and a negative net margin of 431.61%. On average, equities research analysts predict that Vaxart, Inc. will post -0.39 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Vaxart

A number of institutional investors and hedge funds have recently added to or reduced their stakes in VXRT. Geode Capital Management LLC grew its position in Vaxart by 15.8% in the 3rd quarter. Geode Capital Management LLC now owns 2,543,228 shares of the biotechnology company's stock valued at $2,160,000 after buying an additional 346,725 shares in the last quarter. Squarepoint Ops LLC lifted its position in Vaxart by 95.0% in the fourth quarter. Squarepoint Ops LLC now owns 516,798 shares of the biotechnology company's stock worth $342,000 after purchasing an additional 251,789 shares during the period. Raymond James Financial Inc. acquired a new position in shares of Vaxart during the 4th quarter valued at $129,000. Silverarc Capital Management LLC lifted its holdings in Vaxart by 7.8% in the 4th quarter. Silverarc Capital Management LLC now owns 1,077,782 shares of the biotechnology company's stock valued at $714,000 after acquiring an additional 77,782 shares during the last quarter. Finally, Sequoia Financial Advisors LLC boosted its holdings in Vaxart by 140.9% during the fourth quarter. Sequoia Financial Advisors LLC now owns 60,213 shares of the biotechnology company's stock worth $40,000 after buying an additional 35,213 shares in the last quarter. 18.05% of the stock is owned by institutional investors.

Vaxart Company Profile

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.